Valuation: Patrys Limited

Market Cap 23.33M 16.58M 14.49M 13.62M 12.43M 23.33M 1.59B 163M 63.08M 810M 62.27M 60.91M 2.61B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 16.05M 14.03M 13.19M 12.03M 22.58M 1.53B 158M 61.07M 784M 60.29M 58.97M 2.53B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
70.71%
Yield 2024 *
-
Yield 2025 -
1 week-2.94%
Current month+10.00%
3 months-26.67%
6 months+10.00%
Current year+17.86%
1 week 0.03
Extreme 0.033
0.03
1 month 0.03
Extreme 0.03
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.014999
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.56
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
11/8/23 Expiration

Chief Executive Officer

396,132 0.0193%
11/8/23 Expiration

Chief Executive Officer

3,283 0.0002%
6/12/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.94%+10.00%-60.71% 15.86M
-0.07%+5.66%+54.34%+113.69% 74.33B
-1.45%-1.43%+36.82%+80.62% 62.26B
-0.66%+7.14%+39.36%+29.20% 27.72B
-0.15%+0.75%-16.69%+361.67% 26.42B
+2.93%+4.32%+2.18%-3.60% 24.62B
+0.84%+7.70%+26.09%-10.70% 20.72B
+0.87%-2.52%+151.81%+328.17% 15.01B
+1.63%+2.20%+46.92%+170.72% 14.18B
+1.30%-1.61%-10.37%+815.51% 13.48B
Average +0.57%+0.37%+34.05%+182.46% 27.88B
Weighted average by Cap. +0.13%+2.10%+37.24%+150.19%

Financials

2024 2025
Net sales 1.39M 991K 866K 814K 743K 1.39M 94.73M 9.77M 3.77M 48.37M 3.72M 3.64M 156M 829K 589K 515K 484K 441K 828K 56.29M 5.8M 2.24M 28.75M 2.21M 2.16M 92.68M
Net income -3.54M -2.52M -2.2M -2.07M -1.89M -3.54M -240M -24.8M -9.57M -123M -9.45M -9.24M -396M -3.01M -2.14M -1.87M -1.76M -1.61M -3.01M -205M -21.11M -8.15M -105M -8.04M -7.87M -337M
Net Debt -2.24M -1.59M -1.39M -1.31M -1.19M -2.24M -152M -15.7M -6.06M -77.75M -5.98M -5.85M -251M -742K -528K -461K -433K -396K -742K -50.44M -5.2M -2.01M -25.76M -1.98M -1.94M -83.05M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
22/09/26 $0.0330 0.00% 30,299
21/09/26 $0.0330 -2.94% 79,599
18/09/26 $0.0340 0.00% 207,276
17/09/26 $0.0340 0.00% 1,181,719
16/09/26 $0.0340 -2.86% 535,087
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!